SCHEMBL4904585

SCHEMBL4904585

COc1ccc(-c2ccccn2)nc1Br

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 11/20 0.50
SMN1; SMN2 Q16637 10/20 0.50
LMNA P02545 9/20 0.50
KDM4E B2RXH2 6/20 0.50
HTT P42858 4/20 0.50
TP53 P04637 4/20 0.50
TDP1 Q9NUW8 3/20 0.50
ALOX15 P16050 3/20 0.50
CCR1 P32246 2/20 0.50
CCR5 P51681 2/20 0.50
CCR8 P51685 2/20 0.50
ALPL P05186 1/20 0.50
HSP90AA1 P07900 1/20 0.50
ALPI P09923 1/20 0.50
ALPG P10696 1/20 0.50
MAPK1 P28482 1/20 0.50
MAPT P10636 4/20 0.49
POLB P06746 3/20 0.47
CYP1A2 P05177 2/20 0.47
TRPM8 Q7Z2W7 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4902634 0.79 HTT (0.44) L3MBTL1SMN1; SMN2LMNAKDM4EHTT
SCHEMBL25228023 0.77 TDO2 (0.55) L3MBTL1SMN1; SMN2LMNAKDM4EHTT
SCHEMBL2620990 0.76 SMN1; SMN2 (0.43) L3MBTL1SMN1; SMN2LMNAKDM4EHTT
SCHEMBL5464967 0.75 ALDH1A1 (0.50) L3MBTL1SMN1; SMN2LMNAKDM4EHTT
SCHEMBL22901540 0.74 SMN1; SMN2 (0.56) L3MBTL1SMN1; SMN2LMNAKDM4EHTT
SCHEMBL5681545 0.73 SMN1; SMN2 (0.60) L3MBTL1SMN1; SMN2LMNAKDM4EHTT
SCHEMBL6800917 0.73 LMNA (0.50) L3MBTL1SMN1; SMN2LMNAKDM4EHTT
SCHEMBL6815364 0.72 SMN1; SMN2 (0.58) L3MBTL1SMN1; SMN2LMNAKDM4EHTT
SCHEMBL20916320 0.72 KDM4E (0.63) L3MBTL1SMN1; SMN2LMNAKDM4EHTT
SCHEMBL28663560 0.72 KDM4E (0.57) L3MBTL1SMN1; SMN2LMNAKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080108600-A1 Polycyclic Pyridines as Potassium Ion Channel Modulators ICAGEN, INC. (US) 2008-05-08 US disclosed
EP-1737852-A2 POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS Icagen, Inc. (US) 2007-01-03 EP disclosed
WO-2005100349-A2 POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS ICAGEN, INC. (US) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108600-A1 Polycyclic Pyridines as Potassium Ion Channel Modulators KCNJ2, KCNH2, KCNQ1 L3MBTL1 3704/4885SMN1; SMN2 3670/4885LMNA 3338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.